Nuo Therapeutics, Inc.
AURX
Get informed when a big investor buys or sells
+ FollowMarket Cap$62.93M
Close$
Share Statistics
| Market cap | $62.93 Million |
|---|---|
| Enterprise Value | $64.29 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.05 |
| Beta | -104.09 |
| Outstanding Shares | 48,407,917 |
Return
| Return on Equity | 131.08% |
|---|---|
| Return on Assets | -76.63% |
| Return on Invested Capital | -161.32% |
Valuation & Multiples
| P/E Ratio | -31.1 |
|---|---|
| PEG | 54.3 |
| Price to Sales | - |
| Price to Book Ratio | -1.3 |
| Enterprise Value to Revenue | 12.36 |
| Enterprise Value to EBIT | -37.16 |
| Enterprise Value to Net Income | -32 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | -1.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$1.30 M
Average shareholder expectationNext Earnings Call
Expected Date
December 2, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$1.90 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nuo Therapeutics, Inc.
10 employees
CEO: David E. Jorden Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inhere...